Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Jan;47(1):43–47. doi: 10.1136/ard.47.1.43

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

N J McHugh 1, M Csuka 1, H Watson 1, G Belcher 1, A Amadi 1, E F Ring 1, C M Black 1, P J Maddison 1
PMCID: PMC1003442  PMID: 2449871

Abstract

Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belch J. J., Newman P., Drury J. K., McKenzie F., Capell H., Leiberman P., Forbes C. D., Prentice C. R. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet. 1983 Feb 12;1(8320):313–315. doi: 10.1016/s0140-6736(83)91624-0. [DOI] [PubMed] [Google Scholar]
  2. Blunt R. J., George A. J., Hurlow R. A., Strachan C. J., Stuart J. Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome. Br J Haematol. 1980 Aug;45(4):651–658. doi: 10.1111/j.1365-2141.1980.tb07188.x. [DOI] [PubMed] [Google Scholar]
  3. Clifford P. C., Martin M. F., Sheddon E. J., Kirby J. D., Baird R. N., Dieppe P. A. Treatment of vasospastic disease with prostaglandin E1. Br Med J. 1980 Oct 18;281(6247):1031–1034. doi: 10.1136/bmj.281.6247.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Keller J., Kaltenecker A., Schricker K. T., Neidhardt B., Hornstein O. P. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. Arch Dermatol Res. 1985;277(4):323–325. doi: 10.1007/BF00509089. [DOI] [PubMed] [Google Scholar]
  6. Kyle V., Parr G., Salisbury R., Thomas P. P., Hazleman B. Prostaglandin E1 vasospastic disease and thermography. Ann Rheum Dis. 1985 Feb;44(2):73–78. doi: 10.1136/ard.44.2.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  8. Ring E. F., Porto L. O., Bacon P. A. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res. 1981;9(6):393–400. doi: 10.1177/030006058100900601. [DOI] [PubMed] [Google Scholar]
  9. Schrör K., Darius H., Matzky R., Ohlendorf R. The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1981 Jun;316(3):252–255. doi: 10.1007/BF00505658. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES